Key Highlights
- Dr. Helge Bastian appointed as new CEO of iXCells Biotechnologies, a leading cell technology company.
- Dr. Bastian brings extensive leadership experience from life sciences and healthcare, including roles at Thermo Fisher Scientific and Sigma-Aldrich.
- Dr. Lynn Zhang, co-founder and former CEO, will continue to serve on iXCells’ board of directors, aiding in leadership transition.
Source: Business Wire
Notable Quotes
- “I’m impressed with iXCells outstanding scientific and technology expertise and its pragmatic approach to leverage the highly enabling, Nobel Prize winning iPSC reprogramming and genome editing technologies…” – Dr. Helge Bastian, Chief Executive Officer at iXCells Biotechnologies
- “I’m simply amazed by the team’s focus to provide best in class cell-based products and drug development and discovery service solutions…” – Dr. Helge Bastian, Chief Executive Officer at iXCells Biotechnologies
- “To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team…” – Dr. Lynn Zhang, Co-founder and Former CEO at iXCells Biotechnologies
SoH's Take
The appointment of Dr. Helge Bastian as the new CEO of iXCells Biotechnologies marks a significant milestone in the company’s trajectory. Dr. Bastian’s extensive background in life sciences and healthcare, coupled with his leadership roles in several global organizations, positions him uniquely to drive iXCells’ growth and innovation in the field of cell-based technology and drug discovery. This strategic leadership change is poised to enhance iXCells’ capabilities in delivering cutting-edge solutions, particularly in the realm of iPSC reprogramming and genome editing technologies. It’s an exciting time for iXCells, as they continue to expand their impact in developing highly predictive human disease models and novel therapies, particularly for the rare disease community. Dr. Bastian’s vision and expertise are expected to solidify iXCells’ status as a leading provider in the industry, fostering advancements that could be pivotal in the landscape of drug discovery and patient care.
